06978.HK
Immunotech Biopharm Ltd
HKSE · Healthcare · Biotechnology · CN
HKD 0.40
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +38.8%
- EBIT
- +30.7%
- EPS
- -18.2%
- Free cash flow
- -12.6%
- Operating cash flow
- -22.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -13.5%
- EBIT
- +21.6%
- Net income
- -23.5%
- EPS
- -16.7%
- Free cash flow
- +27.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026